The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective ...

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most ...

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while ...

The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer ...